Express Scripts

Vernal Biosciences Announces Strategic Leadership Appointments to Drive Growth in mRNA and LNP Formulation

Retrieved on: 
Wednesday, January 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, LNP, Marketing, EY, Commercial, Business, CFO, Diageo, Messenger, CDMO, Strategic planning, Kodak, United, Rich, GMP, Thermo Fisher Scientific, Express Scripts, Volvo, Management

Vernal Biosciences, a leading manufacturing and services company specializing in mRNA and lipid nanoparticle (LNP) formulation, proudly announces the additions of Sven Lee, Chief Commercial Officer, and Richard P. Hamel, Chief Financial Officer to its leadership team.

Key Points: 
  • Vernal Biosciences, a leading manufacturing and services company specializing in mRNA and lipid nanoparticle (LNP) formulation, proudly announces the additions of Sven Lee, Chief Commercial Officer, and Richard P. Hamel, Chief Financial Officer to its leadership team.
  • His team will help customers define their manufacturing needs and provide creative solutions that leverage Vernal’s innovative technologies and manufacturing operations.
  • Prior to joining Vernal, Sven was a Board Member and the Chief Commercial Officer at BioCina, an Australian based CDMO.
  • Their additions to our team will help Vernal democratize access to high purity mRNA and LNPs for all stages of research and development.”

Visory Health COO Wins Gold Globee® Award, Women in Business

Retrieved on: 
Thursday, November 16, 2023
Vitamins, Supplements, Medical Supplies, Other Retail, Specialty, Other Health, Health, Pharmaceutical, General Health, Retail, Pyramid scheme, Pet, Woman, Google Wallet, AstraZeneca, PepsiCo, Salesforce, Medicine, Express Scripts, IBM, Gold, Prescription, Friends, App Store (iOS/iPadOS), Public health, Apple, Wealth, Sanders, Wallet, Google Play, Female, Pharmacy, Pharmaceutical industry, Visori

Visory Health, a simple, patient-first platform that provides lower prices on prescriptions, announces that its Chief Operating Officer, Debbie Sanders, has received the esteemed Gold Globee® Award for Women in Business in the Female Achiever, Women Helping Women category.

Key Points: 
  • Visory Health, a simple, patient-first platform that provides lower prices on prescriptions, announces that its Chief Operating Officer, Debbie Sanders, has received the esteemed Gold Globee® Award for Women in Business in the Female Achiever, Women Helping Women category.
  • At Visory Health, Sanders leads the technology development for the company’s first-of-its-kind cloud-based adjudication system resulting in an innovative pricing model, cost-effective medications, and transparent transactions.
  • Visory Health has scaled its technology to reach over 3.42 million consumers and work with more than 24,000 pharmacies nationwide — all to improve the health and wellness of American communities.
  • To find providers available in your area, please see a full list of Visory Health supported pharmacies here .

Prime Therapeutics announces Ken Bodmer as chief financial officer

Retrieved on: 
Tuesday, December 5, 2023
Master of Business Administration, CFO, CVS Health, Express Scripts, Patient, Pharmacy, Seton Hall University, Health, American Institute, UnitedHealth Group, Institute of Management Accountants, Business administration, Finance, Villanova University, Accredo, Management, Science, Medco

EAGAN, Minn., Dec. 5, 2023 /PRNewswire/ -- Today, Prime Therapeutics LLC/Magellan Rx Management LLC (Prime/MRx) announces that it has appointed Ken Bodmer as chief financial officer (CFO), effective Dec. 4, 2023.

Key Points: 
  • EAGAN, Minn., Dec. 5, 2023 /PRNewswire/ -- Today, Prime Therapeutics LLC/Magellan Rx Management LLC (Prime/MRx) announces that it has appointed Ken Bodmer as chief financial officer (CFO), effective Dec. 4, 2023.
  • "Ken is an extraordinary leader with a deep understanding of the markets we serve and brings a unique blend of financial and operational expertise coupled with a proven track record of success," said Mostafa Kamal , president and chief executive officer at Prime.
  • Bodmer has more than 20 years of experience in business and financial leadership in both pharmacy benefit management and specialty pharmacy.
  • His previous experience also includes both CFO and chief operating officer roles at Accredo, as well as key financial leadership roles at Medco (now Express Scripts) and Catamaran (now OptumRx).

Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity

Retrieved on: 
Tuesday, December 5, 2023
Hypertension, NYSE, Food, Eli Lilly and Company, Cigna, Overweight, Gastrointestinal disease, Gastroparesis, Cardiovascular disease, Express Scripts, Patient, FDA, Obstructive sleep apnea, Dyslipidemia, LLY, BMI, Lilly, Pancreatitis, Type, Government, Pharmacy, Pharmaceutical industry, Health insurance, Obesity

INDIANAPOLIS, Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity. Zepbound should not be used with other tirzepatide-containing products or any GLP-1 (glucagon-like peptide-1) receptor agonist medicines, and it has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis.

Key Points: 
  • INDIANAPOLIS, Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available.
  • It should be used with a reduced-calorie diet and increased physical activity.
  • We are excited to see growing coverage in the marketplace, giving millions of Americans access to Zepbound."
  • Lilly's commercial savings card program is now available at U.S. pharmacies to help adults who need Zepbound access it.

Cedar Announces Scott Stockberger as Chief Financial Officer

Retrieved on: 
Tuesday, November 28, 2023
Express Scripts, Fintech, Bolt, E-commerce, Stockberg, CFO, Management, Cedar

NEW YORK, Nov. 28, 2023 /PRNewswire/ -- Cedar, an end-to-end healthcare financial engagement platform, today announced that Scott Stockberger has joined as the company's Chief Financial Officer (CFO). In this role, Stockberger will be an integral member of Cedar's Executive Leadership Team, where he will be focused on driving top-line growth, profitability and operational excellence across the organization.

Key Points: 
  • NEW YORK, Nov. 28, 2023 /PRNewswire/ -- Cedar , an end-to-end healthcare financial engagement platform, today announced that Scott Stockberger has joined as the company's Chief Financial Officer (CFO).
  • Scott brings nearly 15 years of finance and corporate development experience, most recently serving as the Chief Financial Officer at Bolt, the one-click checkout platform and shopper identity network for eCommerce.
  • "Cedar is truly transforming the healthcare journey, removing financial burdens and barriers to care, while also adding value for payers and providers," said Stockberger.
  • Stockberger joins Cedar on the heels of several important milestones, including the launch of its Affordability Navigator , a new integrated suite of financial assistance features.

Express Scripts Introduces New Option To Give Clients Maximum Simplicity in Drug Pricing

Retrieved on: 
Tuesday, November 14, 2023
Acquisition, NYSE, Express Scripts, History, Pharmacy, Plasma protein binding, Pharming, PBM, Express, Health insurance, Cigna

ST. LOUIS, Nov. 14, 2023 /PRNewswire/ -- Express Scripts, the pharmacy benefits management (PBM) business of Evernorth, a subsidiary of The Cigna Group (NYSE: CI), today announced a new pharmacy network option, Express Scripts ClearNetworkSM, for its clients – including employers, government organizations, and health plans. It is designed for clients seeking an option for cost-based pricing for prescription drugs and pharmacy services and a seamless experience for their employees and members. Through Express Scripts ClearNetwork, clients pay a straight-forward estimated acquisition cost for individual medications, in addition to a small markup for pharmacy dispensing and service costs.   

Key Points: 
  • Express Scripts ClearNetworkSM offers employers and health plans a new option for simple, "cost-plus" pharmacy pricing for brand, generic, and specialty medications.
  • It is designed for clients seeking an option for cost-based pricing for prescription drugs and pharmacy services and a seamless experience for their employees and members.
  • "This new model differs from other pricing options where Express Scripts negotiates discounts with pharmacies to meet guaranteed rates for clients," Kautzner added.
  • Earlier this year, Express Scripts announced several actions to drive greater transparency and predictability, including ClearCareRx™ which offers another transparent pricing option for clients.

Hagens Berman Sobol Shapiro LLP Announce a Class Action Which May Affect You If You Had A Health Plan That Paid for Generic Prescription Drugs Purchased at CVS Pharmacy

Retrieved on: 
Friday, November 10, 2023
Defendant, Court order, Express Scripts, Pharmacy, Medco, UnitedHealth Group, L.L.C, District court, Local, CLASS, HSP, Court, CVS, CVS Pharmacy, Caremark, PBM, ACTION

prescription drugs purchased at CVS Pharmacy, a

Key Points: 
  • prescription drugs purchased at CVS Pharmacy, a
    class action lawsuit could affect your rights.
  • A CLASS ACTION LAWSUIT is pending in the U.S. District Court for the District of Rhode Island (the "Court").
  • Class Plaintiffs contend that they were overcharged for the generic drugs in the HSP program as a result of Defendants' actions.
  • The complete class definitions are available in the LONG-FORM NOTICE on the website www.CVSHSPClassAction.com or by contacting the Notice Administrator.

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Orphan drug, Research, CVS Caremark, Carcinoma, Dermatology, Express Scripts, Quarter, Prescription, KOL, Probability, Nevoid basal-cell carcinoma syndrome, NESS, Patient, IQVIA, Pharmaceutical industry, Video game, Optum, Galderma

In the third quarter of 2023, TWYNEO maintained a high recurring base of prescribers compared to the second quarter.

Key Points: 
  • In the third quarter of 2023, TWYNEO maintained a high recurring base of prescribers compared to the second quarter.
  • According to IQVIA data, there have been over 13,000 prescriptions of EPSOLAY written in the third quarter of 2023 and over 65,000 prescriptions written to date.
  • Financial Results for the Quarter Ended September 30, 2023
    Total revenue in the three months was $0.2 million, which primarily consisted of licensing revenues from Galderma.
  • General and administrative expenses for the third quarter of 2023 were $1.9 million compared to $1.8 million for the same period in 2022.

INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients

Retrieved on: 
Wednesday, November 1, 2023
FDA, The Guardian Life Insurance Company of America, Food, Medicare, High-performance Integrated Virtual Environment, PBM, Lexicon Pharmaceuticals, Express Scripts, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chronic kidney disease, Type, Risk, Hospital, Patient, Heart failure, Health insurance, Dietary supplement

THE WOODLANDS, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Basic and High Performance formularies for commercially insured patients as of today, November 1, 2023, and in addition to the previously reported Premier Access and Premier Performance national formularies for Medicare patients. These formulary placements will provide access to INPEFA for Express Scripts commercial and Medicare patients in plans that utilize these formularies and who meet the parameters of INPEFA’s FDA-approved indication.

Key Points: 
  • As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023
    THE WOODLANDS, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Basic and High Performance formularies for commercially insured patients as of today, November 1, 2023, and in addition to the previously reported Premier Access and Premier Performance national formularies for Medicare patients.
  • These formulary placements will provide access to INPEFA for Express Scripts commercial and Medicare patients in plans that utilize these formularies and who meet the parameters of INPEFA’s FDA-approved indication.
  • “We continue to make progress in establishing access and reimbursement for INPEFA and are pleased by the Express Scripts decision announced today,” said Lonnel Coats, Lexicon’s chief executive officer.
  • INPEFA is currently commercially available in the U.S.

Walgreens Boots Alliance Names Neal Sample Executive Vice President and Chief Information Officer

Retrieved on: 
Wednesday, November 1, 2023
Health Technology, Retail, Technology, Pharmaceutical, General Health, Supply Chain Management, Online Retail, Convenience Store, Other Retail, Discount, Variety, Supermarket, Other Technology, Specialty, Networks, Health, EVP, Outline of health sciences, Stanford University, Information, EBITDA, Architecture, Express Scripts, Engineering, Multimedia, Bachelor, Sample, Information technology, S-1 Executive Committee, Doctorate, Walgreens Boots Alliance, CIO, Growth, Trustee, Yahoo!, Executive Committee, American Express, University of Health Sciences and Pharmacy in St. Louis, University, EBay, WBA, Patient, Computer science, Management, Pharmacy, Science, Agile, Northwestern Mutual

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today named Neal Sample as its new Executive Vice President and Chief Information Officer (CIO), effective immediately.

Key Points: 
  • Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today named Neal Sample as its new Executive Vice President and Chief Information Officer (CIO), effective immediately.
  • View the full release here: https://www.businesswire.com/news/home/20231101756071/en/
    Neal Sample named Walgreens Boots Alliance CIO (Photo: Business Wire)
    Sample will report to Tim Wentworth, Chief Executive Officer (CEO) of WBA, as a member of the Executive Committee and serve on the IT Governance Committee.
  • Sample is an award-winning technologist and seasoned executive who has a strong track record of driving growth and innovation.
  • Sample is a thought leader in information technology, holding more than a dozen patents as the author of various published works.